211.76 +0.18 (0.09%)
After hours: 7:43PM EDT
Commodity Channel Index
|Bid||210.30 x 800|
|Ask||211.58 x 1300|
|Day's Range||206.85 - 212.71|
|52 Week Range||166.30 - 244.99|
|Beta (5Y Monthly)||0.90|
|PE Ratio (TTM)||16.43|
|Earnings Date||Apr 29, 2020|
|Forward Dividend & Yield||6.40 (3.12%)|
|Ex-Dividend Date||May 14, 2020|
|1y Target Est||244.40|
UnitedHealth Group Chief Scientific Officer Ken Ehlert joins Yahoo Finance’s Anjalee Khemlani and Seana Smith to discuss the new testing kit that will enable patients to test themselves for the virus at home.
Here’s what you need to know about the coronavirus outbreak to navigate the markets today. • U.K. Prime Minister Boris Johnson has been admitted to the hospital after experiencing what a spokesperson called “persistent symptoms” of Covid-19. • The American economy won’t begin to recover until there’s a “highly effective drug in the hands of doctors that can mitigate the risk,” of coronavirus infection, former head of the Food and Drug Administration, Dr. Scott Gottlieb, said on CBS’ Face the Nation Sunday.
At least three clinical trials for hydroxychloroquine are trying to establish whether the decades-old malaria medication can prevent COVID-19 infections in frontline health-care workers as hospitals across the country scramble to secure enough gowns and masks for their employees.
Editorial Assistant James Li seeks good investing opportunities using GuruFocus’ All-in-one Screener Continue reading...
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
The drug will rely on Seattle-based Adaptive’s immune medicine platform to identify antibodies that neutralize the virus using samples taken from patients who have already recovered from COVID-19.
Amgen and Adaptive Biotechnologies teamed up Thursday to seek a coronavirus treatment developed from recovered Covid-19 patients. Amgen and Adaptive shares rose.
U.S. biotechnology company Amgen Inc. (AMGN) is teaming up with Adaptive Biotechnologies Corp. (ADPT) to discover a drug to potentially treat coronavirus patients.The two companies announced Thursday they signed a Memorandum of Understanding to enable them to start work immediately due to the rapid spread of the coronavirus around the world. Terms of the agreement are not being disclosed. Amgen and Adaptive Biotechnologies join a list of companies partnering up to develop a COVID-19 drug.The collaboration brings together Adaptive's proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen's expertise in immunology and novel antibody therapy development.“Working with Adaptive and using their viral-neutralizing antibody platform will expedite our ability to bring a promising new medicine into clinical trials as quickly as possible," said Robert A. Bradway, chairman and chief executive officer at Amgen.The partnership will combine their expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the disease and can be given to people who have heightened risk of exposure to SARS-CoV-2, such as healthcare workers.Overall Wall Street analysts have a Moderate Buy consensus rating for Amgen split into 14 Buys, 4 Holds and 1 Sell. The $246.56 average price target sees room for 18% upside potential in the stock in the next 12 months (See Amgen stock analysis on TipRanks)Related News: Demand for Roche’s COVID-19 Tests Exceeding Capacity; 5-Star Analyst Says ‘Buy’ CryoLife Pre-Releases Low 1Q20 Revenues, Pulls FY20 Guidance Analyst Impressed by Sorrento’s COVID-19 Pipeline, Says ‘Buy’ More recent articles from Smarter Analyst: * Tesla: Despite Record Q1 Numbers, Uncertainty Looms Ahead * Is 14% Potential Upside Good Enough to Risk Buying Zoom Stock? This Analyst Says Yes * GlaxoSmithKline, Vir Biotech Team Up in Hunt For Coronavirus Treatment * This Penny Stock Joins the Fight Against Coronavirus; Analyst Sees Triple-Digit Upside
Shares of Amgen Inc. gained 1.2% in trading on Thursday after the drugmaker announced that it is collaborating with Adaptive Biotechnologies Corp. to discover and develop antibodies that can be used to prevent or treat COVID-19. Adaptive's stock was down 0.9%. Financial terms of the exclusive collaboration will be finalized "in the coming weeks," the companies said. "Working with Adaptive and using their viral-neutralizing antibody platform will expedite our ability to bring a promising new medicine into clinical trials as quickly as possible," Robert Bradway, Amgen's chairman and CEO, said in a statement. Year-to-date, Amgen's stock is down, shares of Adaptive have dropped 8%, and the S&P 500 has tumbled 23%.
Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies (NASDAQ:ADPT) today announced a collaboration aimed at helping address the COVID-19 pandemic. The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. The mutually exclusive collaboration brings together Adaptive's proprietary immune medicine platform for the identification of virus-neutralizing antibodies with Amgen's expertise in immunology and novel antibody therapy development. Given the rapidly rising incidence of COVID-19 around the world, the companies will begin work immediately and finalize financial details and terms in the coming weeks.
Amgen (NASDAQ:AMGN) today announced that it has consummated the purchase from Astellas of 49% of shares of Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas established in 2013. AABP, which is now a wholly-owned Amgen affiliate in Japan renamed Amgen K.K., has enabled Amgen to build a strong presence in Japan as it advances treatments for serious illnesses.
Amgen stock is facing concerns that biosimilars could chip away at some of its biggest moneymakers. Is it time to buy shares of the biotech company?
Amgen (NASDAQ:AMGN) today announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK (BEIJERINCK) study evaluating the efficacy and safety of Repatha® (evolocumab) in patients who are human immunodeficiency virus-positive (HIV+) and have high low-density lipoprotein cholesterol (LDL-C) despite stable background lipid-lowering therapy.1 The study demonstrated that treatment with Repatha significantly reduced LDL-C. The results were featured as an oral presentation during the virtual American College of Cardiology's 69th Annual Scientific Session from March 28-30, 2020 with publication in the Journal of the American College of Cardiology (JACC) on March 30, 2020.
As the government prepares to bail out industries amid the Covid-19 pandemic, stock buybacks are falling out of favor. One sector that does a lot of repurchases? The biopharma industry.
With the COVID-19 crisis sending the U.S. economy in a recession, we're looking at what companies managed to thrive during the last recession for guidance.
Biotech company Amgen is committing $12.5 million to support relief efforts to address needs in communities impacted by the COVID-19 pandemic.
Amgen (NASDAQ:AMGN) and the Amgen Foundation today announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic. The funds will be used to support emergency response efforts in Amgen's U.S. and international communities, patient-focused organizations that are mounting their own response efforts, and international relief efforts by Direct Relief and International Medical Corps. The Amgen Foundation will also match donations made by Amgen staff around the globe who wish to contribute their own funds to the relief efforts.
Technical analysis offers unique insights into market trends, especially in times of chaos. Why three practitioners see support for the S&P 500 around 2300. What the charts say about oil, emerging markets, health care, Walmart.